Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide vs Insulin Glargine in T2D with Increased CV Risk
NCT03730662Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2018
- Primary completion
- Jan 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of tirzepatide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Hemoglobin A1c at 52 weeks. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03730662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03730662.